Table 3.
Comparison of similar studies performed in patients with MDS or MDS/MPN and the present series.
| MANGAONKAR13 | WUDHIKARN12 | XICOY/Present series | ||||
|---|---|---|---|---|---|---|
| n=778 | n=859 | n=815 | ||||
| SF3B1 MUTMDS/MPNvs | CMMLSF3B1MUTvs | CMML with RS/SF3B1 vs | ||||
| SF3B1 WTMDS/MPN | SF3B1 mut MDS | CMML SF3B1 WT | SF3B1 MUT MDS-RS | CMML without RS/SF3B1 | MDS with RS/SF3B1 | |
| CLINICAL DIFFERENCES | Hemoglobin | |||||
| Platelet | ||||||
| Sex | WBC | |||||
| Hemoglobin | Hemoglobin | AMC and % | ||||
| WBC | Sex | WBC | Leukocyte | ANC | Age | |
| ANC | WBC ANO | ANC | Monocyte count Platelet count | PB blasts | Gender | |
| AMC | AMC | AMC | IMCs | BM blasts | WBC | |
| Platelet | Platelet | Platelet count | PB blasts | FAB subtype | AMC and% | |
| BM RS | PE blats | RS | BM blasts | Dysplastic lines | IPSS-R | |
| PB blats | BM blasts | FAB subtype | RS (median, %) | |||
| BM blasts | Cytogenetic risk | Dyserythropoieseis | ||||
| Abnormal karyotype | Dysgranulopiesis | |||||
| CPSS | ||||||
| IPSS-R (low/High) | ||||||
| MOLECULAR DIFFERENCES | - |
JAK2 V617F
(enriched in SF3B1 MUT MDS/MPN) |
ASXL1 and SRSF2
(enriched in CMML SF3B1 WT |
RUNX1
(enriched in CMML SF3B1WT) |
DNMT3A, SF3B1
(enriched in CMML-RS/SF3B1 RUNX1, SETBP1 (enriched in CMML without RS/SF3B1 |
TET2 (enriched in CMML-RS/SF3B1) |
| AML-T | Lower | NS | Lower | Higher | Lower | NS |
| os | Higher | NS | NS (trend) | NS (trend) | Higher | NS |
MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; CMML, chronic myelomonocytic leukemia; MDS, Myelodysplastic syndrome; RS, ring sideroblasts; WBC, leukocyte count; ANC, absolute neutrophil count; AMC, absolute monocyte count; BM, bone marrow; RS, ring sideroblasts; PB, peripheral blood; FAB, French-American-British; IMC, immature myeloid cells; CPSS, CMML-Prognostic Score System; IPSS-R, Revised International Prognostic Score; AML-T, acute myeloid leukemia transformation; OS, overall survival.